- Home
- WST vs EQR Comparison
WST vs EQR Comparison
Compare WST & EQR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- WST
- EQR
- Stock Information
- Founded
- WST 1923
- EQR 1993
- Country
- WST United States
- EQR United States
- Employees
- WST N/A
- EQR N/A
- Industry
- WST Medical/Dental Instruments
- EQR Real Estate Investment Trusts
- Sector
- WST Health Care
- EQR Real Estate
- Exchange
- WST Nasdaq
- EQR Nasdaq
- Market Cap
- WST 23.2B
- EQR 27.9B
- IPO Year
- WST N/A
- EQR 1993
- Fundamental
- Price
- WST $322.46
- EQR $73.75
- Analyst Decision
- WST Buy
- EQR Buy
- Analyst Count
- WST 3
- EQR 19
- Target Price
- WST $460.33
- EQR $75.22
- AVG Volume (30 Days)
- WST 519.5K
- EQR 1.4M
- Earning Date
- WST 10-24-2024
- EQR 01-28-2025
- Dividend Yield
- WST 0.26%
- EQR 3.66%
- EPS Growth
- WST N/A
- EQR 35.67
- EPS
- WST 6.74
- EQR 2.44
- Revenue
- WST $2,876,400,000.00
- EQR $2,940,829,000.00
- Revenue This Year
- WST N/A
- EQR N/A
- Revenue Next Year
- WST $6.22
- EQR $4.01
- P/E Ratio
- WST $47.85
- EQR $30.26
- Revenue Growth
- WST N/A
- EQR 3.33
- 52 Week Low
- WST $265.00
- EQR $57.33
- 52 Week High
- WST $413.70
- EQR $78.83
- Technical
- Relative Strength Index (RSI)
- WST 53.52
- EQR 46.72
- Support Level
- WST $313.92
- EQR $72.90
- Resistance Level
- WST $326.58
- EQR $78.32
- Average True Range (ATR)
- WST 7.66
- EQR 1.10
- MACD
- WST -0.61
- EQR -0.22
- Stochastic Oscillator
- WST 84.86
- EQR 15.68
About WST West Pharmaceutical Services Inc.
West Pharmaceutical Services is based in Pennsylvania, U.S., and is a key supplier to firms in the pharmaceutical, biotechnology, and generic drug industries. West sells elastomer-based packaging components (including stoppers, seals, and plungers), non-glass containment solutions, and auto-injectors for injectable drugs. The company reports in two segments: proprietary products (about 80% of total revenue) and contract-manufactured products (about 20% of total revenue). It generates approximately 55% of its revenue from international markets and 45% from the United States.
About EQR Equity Residential of Beneficial Interest
Equity Residential owns a portfolio of 299 apartment communities with around 80,000 units and is developing three additional properties with 977 units. The company focuses on owning large, high-quality properties in the urban and suburban submarkets of Southern California, San Francisco, Washington, D.C., New York, Seattle, and Boston.